All In Biotech

Drug Trial Radar · NCT05787574

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Phase 2 Study Bridging Pre-Transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Mar 15, 2023

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Joseph OvedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sobi, Inc.
First posted
Mar 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Funding Source - FDA OOPD"

Conditions

  • Primary Immune Regulatory Disorder
  • Autoimmune Lymphoproliferative
  • Immune System Diseases

Interventions

  • EmapalumabDrug

    Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.

  • Fludarabine and DexamethasoneDrug

    Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.

  • Allogeneic hematopoietic stem cell transplant (allo-HCT)Procedure

    Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EngraftmentTime frame: Day 100 post-alloHCT

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey · Active not recruiting

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey · Active not recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey · Active not recruiting

  • Memorial Sloan Kettering Suffolk - Commack

    Commack, New York · Active not recruiting

  • Memorial Sloan Kettering Westchester

    Harrison, New York · Active not recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Memorial Sloan Kettering Nassau

    Rockville Centre, New York · Active not recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.